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Abstract
Background: The vascular disease in-stent restenosis (ISR) is characterized by formation of neointima and adverse
inward remodeling of the artery after injury by coronary stent implantation. We hypothesized that the analysis of
gene expression in peripheral blood mononuclear cells (PBMCs) would demonstrate differences in transcript
expression between individuals who develop ISR and those who do not.
Methods and Results: We determined and investigated PBMC gene expression of 358 patients undergoing an
index procedure to treat in de novo coronary artery lesions with bare metallic stents, using a novel time-varying
intercept model to optimally assess the time course of gene expression across a time course of blood samples.
Validation analyses were conducted in an independent sample of 97 patients with similar time-course blood
sampling and gene expression data. We identified 47 probesets with differential expression, of which 36 were
validated upon independent replication testing. The genes identified have varied functions, including some related
to cellular growth and metabolism, such as the NAB2 and LAMP genes.
Conclusions: In a study of patients undergoing bare metallic stent implantation, we have identified and replicated
differential gene expression in peripheral blood mononuclear cells, studied across a time series of blood samples.
The genes identified suggest alterations in cellular growth and metabolism pathways, and these results provide the
basis for further specific functional hypothesis generation and testing of the mechanisms of ISR.
Background
Cardiovascular disease is the leading cause of death in
western countries and a major cause of morbidity and
mortality world-wide. Studying coronary atherosclerotic
disease (CAD) is challenging for several reasons, since it
has substantial environmental and genetic components.
Furthermore, despite the nearly universal presence of
coronary atherosclerosis, particularly as individuals age,
cardiovascular events such as acute coronary syndromes,
sudden death and the need for revascularization therapy
only occur in some individuals, highlighting the diffi-
culty in precisely defining atherosclerosis phenotypes.
In symptomatic patients, revascularization therapy is
often required, and percutaneous intervention with bal-
loon angioplasty and stent implantation is a cornerstone
of therapy. In-stent restenosis (ISR) is a late complica-
tion of stent implantation in which inflammatory and
proliferative responses to the vascular injury caused by
angioplasty and stenting lead to neointimal hyperplasia
within the stent and at its edges over the following
weeks and months. Many of the same inflammatory and
proliferative processes are activated in the development
of atherosclerosis but occur over years or decades. ISR
is characterized by proliferative responses to the vascu-
lar wound incurred as a result of stent implantation [1].
Therefore, ISR may be viewed as a model phenotype of
vascular wound repair for which the mechanisms repre-
sent part of the pathologic picture of atherosclerosis,
with relatively accelerated wound repair responses
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operative in the vascular wall and in peripheral blood
leukocytes.
In the analysis reported here, we apply a novel
method to analyze time-course gene expression data to
gene expression profiles of peripheral blood mononuc-
lear cells (PBMCs) of patients enrolled in our study of
ISR. The results of the discovery transcriptome analysis
of the CardioGene Study were tested for replication in
an independent sample of Icelandic patients. We ulti-
mately identified and validated a set of 32 genes that
are temporally differentially expressed in the blood of
patients who develop ISR after stenting, compared to
those who do not develop ISR, highlighting the impor-
tance of cellular growth pathways and identifying sev-
eral biologic candidates for further mechanistic
investigation.
Results
Microarray data quality control and filtering
In the CardioGene Study, 312 patients were included
(52 with ISR, and 260 who did not develop ISR, as
defined by criteria for clinical restenosis [2]) after quality
control filtering (Table 1). All 312 patients had baseline
gene expression profile data (Figure 1a). Of these, 203
had a blood sample and high quality gene expression
profile data at early follow-up (2-4 weeks post-stent),
and 166 had high quality gene expression profile data at
both early follow-up and late follow-up (6 months post-
stent). A total of 681 samples were included in the time
course analysis. Box plots showing the distributions of
the early and late follow-up times are presented in
Figure 1b. From the deCODE sample of patients in Ice-
land, 97 patients were enrolled and had high quality
gene expression profiles at baseline (28 with ISR, 69
without ISR). Of these, 86 patients had a follow-up
blood sample and acceptable gene expression data at
6 months post-stent. Thus, a total of 183 samples were
included in the replication analysis.
CardioGene discovery analysis of time-course RNA
expression in PBMCs
Applying the time varying intercept model, 46 probes, cor-
responding to 42 distinct genes, were found to be signifi-
cant at FDR adjusted q-value less than 0.05 out of 12467
probe sets that passed the quality control (Additional File
1). Two patterns of gene expression were observed, with
some genes showing divergent gene expression patterns
across the time course (Figure 2a) and others showing
consistently differential gene expression over the time
course (Figure 2b). Descriptions of the genes to which
these probe sets map are provided in Additional File 1.
Replication analysis using deCODE time course samples
Among 46 significant probe sets identified in the Cardi-
oGene time-course analysis, 36 probe sets had FDR
adjusted q-value less than 0.05 in the deCODE replica-
tion analysis (Figure 3). Gene expression patterns were
largely consistent with the patterns observed in the Car-
dioGene discovery analysis (Figure 2c and 2d). The 36
probe sets mapped to 32 unique genes (Table 2).
Annotation of Genes Identified
Using the DAVID/EASE annotation tool, several cate-
gories of genes were identified, falling into multiple gene
ontology classifications. No single category achieved a
significance score indicating statistically significant over-
representation of a specific gene ontology, and several
gene ontology classes showed multiple genes (Additional
File 2). The categories with the highest representation
(i.e. the largest number of genes mapping to these
ontologies) included cell growth and/or maintenance,
cellular metabolism, catalytic activity, nucleotide and
Table 1 Clinical characteristics of the CardioGene and deCODE cohorts
CardioGene N = 312 deCODE N = 97
Number of female (% female) 100 (32.0%) 19 (19.6%)
Age (mean ± sd) 65.6 (10.4) 64.8 +/- 10.0
Diabetes 91 (29.2%) 12 (12.5%)
Hypertension 213 (68.2) 58 (64%)
Ever smoked 194 (62.1%) 23 (48%)
Hyperlipidemia 241 (77.2%) 47 (48.4%)
Prior ISR (N, %) 10 (4.3%) ——
ISR 52 (16.7%) 28 (28.9%)
Acute coronary syndrome at time of index PCI 64 (20.5%) ——
Reference diameter (mean ± sd) 2.74 mm +/- 0.74 mm 2.71 mm +/- 0.050 mm
Lesion length (mean ± sd) 9.4 mm +/- 5.3 mm 12.7 mm +/- 8.14 mm
LAD location (% with stent in LAD) 126 (40.6%) 52 (53.6%)
Post-stent % stenosis in patients with ISR 10.96 mm +/- 6.2 mm 6.0 mm +/- 12.7 mm
Number of timepoints at which PBMC gene expression measured 3 2
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nucleic acid metabolism, transport, protein binding and
cellular binding. Genes with prior evidence of expression
in the arterial wall after vascular injury included the
NAB2 and LAMP2 genes, with data in the prior litera-
ture suggestive of functional relevance of these genes, by
mediating proliferative responses and recruitment of
PBMCs to injured endothelium, respectively [3-13]
(Figure 4).
Sensitivity Analysis
In a sensitivity analysis, we found that the median num-
ber of significant probe sets using the same criteria of
FDR 0.05 was only 2, the mean was 3.04, and the maxi-
mum number was 14 in one iteration, demonstrating a
significantly low likelihood that the probesets we identi-
fied and replicated were identified due to chance.
Hypothesis-driven analysis of gene expression
We compared our results to published studies examin-
ing gene expression in ISR, chiefly in human vascular
tissue samples [14,15]. In one study, peripheral blood
total leukocytes were also examined [14]. In the Cardi-
oGene baseline blood sample, genes reported by
Ashley et al were examined [15], and none were signif-
icantly differentially expressed in the baseline blood
sample or in our timecourse results. In another study
by Zohlnhofer et al [14], gene expression data from
neointimal vascular tissue and peripheral blood leuko-
cytes were reported. We examined those genes meet-
ing a Bonferroni multiple testing correction from this
discovery report and did not find overlap with our
gene expression findings.
Discussion
Using a repeated sampling study design, we investigated
PBMC transcript expression in patients undergoing
stent implantation, using a novel time-course analysis
method. We identified a set of 42 genes with differential
temporal expression among patients with and without
ISR at one year follow-up in a discovery analysis of the
CardioGene Study. Independent replication testing in an
Icelandic sample confirmed differential expression of 36
probesets mapped to 32 genes. The gene expression pat-
terns over time may be of interest as well, with consis-
tently expressed genes representing gene expression
data that may be able to predict ISR and differentially
expressed genes over the time course representing genes
with possible direct functional roles in the development
of ISR, both of which require further investigation to
explore more fully.
Gene expression profiling with DNA microarray tech-
nology is a popular tool to monitor the expression level
of thousands of genes simultaneously and has been
applied in cardiovascular research, to detect patterns of
gene expression indicative of underlying disease states
[16-21]. Since the data generated represent the temporal
abundance of mRNA levels in the sample, measure-
ments of the change of this abundance over the course
of disease progression (or any biological process) is
therefore both possible and of great scientific interest
using this technology. In fact, Yuan and Kendziorski
[22] reported that more than one-third of the experi-
ments catalogued in the Gene Expression Omnibus
(National Center for Biotechnology Information; http://
www.ncbi.nlm.nih.gov/geo/) are from experiments that
measure gene expression over time. Early time-course
RNA expression studies have focused on identifying
clusters of genes with a similar pattern over time
[14,23,24]. More recently, detecting a differential gene
expression pattern over time between several biological
groups has become an interesting goal of time-course
gene expression data.
To detect differential gene expression pattern over
time, we used a time-varying intercept model which can
account for differences in sample intervals between
patients. The term “differential gene expression pattern
over time” can be interpreted in several ways to form
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Figure 1 The CardioGene Study Design and intervals for blood
sampling. (a) Times of blood sampling and clinical follow-up. Blood
draws occurred at times T0 (pre-stent), T1 (2-4 weeks post-stent)
and T2 (six months post-stent) (b) Distribution of the intervals for
blood sampling from baseline to early follow-up (2-4 weeks post-
stent) and late follow-up (6-12 months) time points, are shown for
the CardioGene Study.
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suitable questions and, thus, the hypotheses are depen-
dent on the particular experiment under consideration.
We considered two related questions where each can
roughly correspond to the main effect of the group, and
the interaction between group and time points. Consider,
for example, a gene with exactly the same expression pat-
tern over time in both groups, but the first group has a
higher expression than the second group, consistently
over all time points. This is a gene that shows the main
effect of the group. On the other hand, consider another
gene with similar expression level at two time points, 1
and 2, but this gene’s expression increases from time 1 to
2 in one group but decreases in another group. This
group-by-time interaction cannot be examined by
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Figure 2 Patterns of time course results for three probe sets in the CardioGene and deCODE studies. The color of the lines plotted is red for
ISR, blue for non-ISR, and black for the model fitted to all patients, under the null hypothesis. Probeset 201222_s_at (a) shows a divergent pattern of
gene expression between individuals who develop ISR and those who do not, whereas 203605_at (b) shows consistently differential expression across
the timecourse. Gene expression for probe set 218047_at shows similar gene expression patterns in both the CardioGene (c) and deCODE (d) cohorts.
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methods that only test the main effect of the group. The
time-varying intercept model we used can detect both
the main effect and group-by-time interaction. This
method, however, requires a large number of bootstrap
resampling to evaluate the significance level of the differ-
ence between groups, which can be computationally
challenging especially when a large number of genes are
tested.
Of the genes we identified, the most extensive prior
literature in vascular disease was found for the NAB2
gene, which is also known as EGR1 binding protein 2.
Early growth response (EGR) genes, which are transcrip-
tion factors that are implicated in a wide variety of pro-
liferative and differentiative processes [15]. Nab proteins
are necessary for Schwann cells to exit the cell cycle
and generate a myelin-specific gene profile and are key
regulators of the myelination process of peripheral
nerves [25]. NAB2 is expressed in vascular smooth mus-
cle cells in response to injury [3-12,26] and EGR1 has
been identified in a microarray study of in vitro smooth
muscle cell proliferation [27]. The LAMP2 gene product
protects the lysosomal membrane from proteolytic
enzymes within lysosomes and also functions as a recep-
tor for proteins to be imported into lysosomes [28].
Mutations in the LAMP2 gene have been identified in
patients with hypertrophic cardiomyopathy [29], and the
gene product mediates adherence of PBMCs to the vas-
cular endothelium [13]. Cellular adhesion to the vascular
endothelium has been well-described in animal models
and post-mortem human examinations, in atherogenesis
and acute vascular injury [30,31]. In the latter, the
extent of leukocyte adhesion is predictive of the degree
of subsequent neointimal hyperplasia, which is the key
lesion of ISR.
Some genes identified have no apparent role in vascular
biology, such as VPS26, VPS41, SRP54, and RAD23B, and
comparison to previously published reports in the litera-
ture do not show differential gene expression in other
studies of restenosis, although these investigations were
conducted primarily on vascular tissues or culture vascu-
lar smooth muscle cells rather than peripheral blood
[17,18,27,32]. The VPS26 and VPS4 genes belongs to a
group of vacuolar protein sorting genes and may have a
role in lysosome maintenance [33], and SRP54 is a pro-
tein in the signal recognition particle, which directs
secretory proteins to membranes as they emerge from
the ribosome [34]. Specific vascular or inflammatory cell
function has not been described, but derangement of
these basic cellular processes may impact vascular and
other physiologic functions adversely. RAD23B has a role
in DNA (nucleotide excision) repair, and genetic variants
in RAD23B have been associated with several solid
tumors [35-38]. The association with cancer would sug-
gest a possible link to excess proliferative mechanisms in
vascular wound repair, as has been described for many
other cell cycle regulatory genes [39]. Genetic variants in
other genes we identified are also associated with human
diseases. Several genetic variants in ACADM have been
associated with medium-chain acyl-CoA dehydrogenase
activity, but there is no known vascular implication of
this disorder [40]. Variants in PCMT1 and FOLR2 have
been associated with neural tube defects [41-43], with no
known vascular phenotype in these cases. Overall the
findings of this study are hypothesis-generating and can
be used to support the rational for investigating the func-
tion of specific genes and pathways in adverse vascular
remodeling, which is relevant to both ISR and more gen-
eral CAD phenotypes.
We compared the results of our study to previously
published reports of transcriptome analysis in ISR. Our
results were negative for replication of these studies
which focused primarily on vascular tissue samples, in
relatively small sample sets. In one study, peripheral
blood total leukocyte gene expression was studied in
10 patients with ISR and atherectomy specimens [23].
While a high degree of correlation between peripheral
blood leukocyte and arterial neointima tissue gene
expression was identified in a subset of genes, these
findings were based upon single measurements in a
small sample size and were not replicated in the original
report. These prior reports highlight the major difficulty
of studying vascular tissues, since access to these tissues
in adequately large sample sizes is limited.
Vascular biopsy and atherectomy are performed infre-
quently as part of routine clinical care and would not
support well-powered studies of vascular tissues. Tissue
sampling over a time course is not clinically indicated or
possible. Additionally, a large degree of intra-individual
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Figure 3 Genes identified in the CardioGene discovery analysis
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replicated in the deCODE analysis.
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variability in gene expression was noted in these prior
studies of vascular tissues, making replication testing cri-
tical, yet this cannot be done without access to additional
tissues samples. In our study, we analyzed peripheral
blood leukocytes, specifically focusing on the mononuc-
lear fraction which contains primarily B and T lympho-
cytes and monocytes. Although the analysis of peripheral
blood cells would ideally be complemented by similar
studies in vascular tissues, studying gene expression
profiles in blood leukocytes is biologically relevant due to
well-defined interactions with the arterial wall, particu-
larly in the setting of vascular injury and repair as in the
setting of ISR [17]. The overlap between vascular and
blood gene expression in one prior transcriptome analy-
sis of ISR was supportive of our rationale to study
PBMCs. For these reasons, and with the additional prior
knowledge that inflammation plays a significant role in
the development of ISR, we undertook a study of PBMCs
Table 2 Validated genes x(32 genes, 36 probesets) with annotation information and gene expression patterns, as
shown in Figure 2
Affymetrix probesets Gene Symbol Gene Name Gene expression pattern
202502_at ACADM acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain Consistent (ISR > No-ISR)
221504_s_at ATP6V1H ATPase, H+ transporting, lysosomal 50/57 kDa, V1 subunit H Consistent (ISR > No-ISR)
202654_x_at AXOT axotrophin Consistent (ISR > No-ISR)
212460_at C14orf147 chromosome 14 open reading frame 147 Divergent (ISR > No-ISR)
203994_s_at C21orf2 chromosome 21 open reading frame 2 Consistent (No-ISR > ISR)
203996_s_at C21orf2 chromosome 21 open reading frame 2 Consistent (No-ISR > ISR)
208374_s_at CAPZA1 capping protein (actin filament) muscle Z-line, alpha 1 Consistent (ISR > No-ISR)
217886_at EPS15 epidermal growth factor receptor pathway substrate 15 Consistent (ISR > No-ISR)
218646_at FLJ20534 hypothetical protein FLJ20534 Consistent (ISR > No-ISR)
204829_s_at FOLR2 folate receptor 2 (fetal) Consistent (ISR > No-ISR)
220131_at FXYD7 FXYD domain containing ion transport regulator 7 Consistent (No-ISR > ISR)
217814_at GK001 GK001 protein Consistent (ISR > No-ISR)
218092_s_at HRB HIV-1 Rev binding protein Consistent (ISR > No-ISR)
212411_at IMP4 U3 snoRNP protein 4 homolog Divergent (No-ISR > ISR)
200821_at LAMP2 lysosomal-associated membrane protein 2 Consistent (ISR > No-ISR)
203276_at LMNB1 lamin B1 Consistent (ISR > No-ISR)
214773_x_at MGC3794 putative MAPK activating protein Consistent (ISR > No-ISR)
212803_at NAB2 NGFI-A binding protein 2 (EGR1 binding protein 2) Consistent (No-ISR > ISR)
203371_s_at NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 12 kDa Consistent (ISR > No-ISR)
218047_at OSBPL9 oxysterol binding protein-like 9 Consistent (ISR > No-ISR)
221123_x_at PBF papillomavirus regulatory factor PRF-1 Consistent (No-ISR > ISR)
208857_s_at PCMT1 protein-L-isoaspartate (D-aspartate) O-methyltransferase Consistent (ISR > No-ISR)
205202_at PCMT1 protein-L-isoaspartate (D-aspartate) O-methyltransferase Consistent (ISR > No-ISR)
209345_s_at PI4KII phosphatidylinositol 4-kinase type II Consistent (No-ISR > ISR)
201222_s_at RAD23B RAD23 homolog B (S. cerevisiae) Divergent (ISR > No-ISR)
201223_s_at RAD23B RAD23 homolog B (S. cerevisiae) Consistent (ISR > No-ISR)
209207_s_at SEC22L1 SEC22 vesicle trafficking protein-like 1 (S. cerevisiae) Consistent (ISR > No-ISR)
217758_s_at SMBP SM-11044 binding protein Consistent (ISR > No-ISR)
203605_at SRP54 signal recognition particle 54 kDa Consistent (ISR > No-ISR)
212513_s_at USP33 ubiquitin specific protease 33 Consistent (ISR > No-ISR)
201807_at VPS26 vacuolar protein sorting 26 (yeast) Consistent (ISR > No-ISR)
210849_s_at VPS41 vacuolar protein sorting 41 (yeast) Divergent (ISR > No-ISR)
205126_at VRK2 vaccinia related kinase 2 Divergent (ISR > No-ISR)
216304_x_at YME1L1 YME1-like 1 (S. cerevisiae) Consistent (ISR > No-ISR)
201351_s_at YME1L1 YME1-like 1 (S. cerevisiae) Consistent (ISR > No-ISR)
222294_s_at RAB27A Consistent (ISR > No-ISR)
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Figure 4 Gene expression for the top eight genes, NAB2 and LAMP2. Gene expression plots are shown for the top eight ranked genes, and
NAB2 and LAMP2 genes are shown together, as these genes have known functions relevant to ISR. Gene expression data is shown for both
cohorts across the time course of samples in each study. For each gene, expression levels are shown on the y-axis as the log 2 of normalized
gene expression (GE), and the timepoints shown on the x-axis of each plot correspond to baseline (BL), early follow-up (EF), and late follow-up
(LF) timepoints, although data was analyzed across the continuous timeframe of follow-up blood sampling, rather than categorically as is
depicted here for illustration purposes. The box plots are plotted with the whiskers at 1.5 times the interquartile range.
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in several hundred patients, with adequately powered
replication testing for our top discovery findings. Addi-
tionally, we use a time course analysis method that
improved our ability to detect gene expression signals
between the two comparison groups, overcoming some
of the difficulty of substantial variability in single point
microarray gene expression data.
To address the possibility of false positives identified
with our statistical methods, we conducted replication
analyses in the independent sample of deCODE samples
and we conducted bootstrap resampling to assess signifi-
cance of the findings. Through this sensitivity analysis, we
demonstrated that the validation of 36 probe sets is not
likely to be due to chance. Additional potential limitations
of this study of ISR are the use of a clinical restenosis out-
come, rather than an angiographic outcome, in which
clinically silent ISR may have been missed, and the choice
of tissue analyzed, as discussed. The CardioGene and
deCODE cohorts differ in the incidence of ISR (16.7% in
the CardioGene Study and 28.8% in deCODE) with the
patients in the deCODE sample showing overall lower
residual percent stenosis in the treated lesion after stent
implantation. Also, the proportions with hyperlipidemia
and diabetes differ. However, despite the differences in the
cohorts, we find replication of a substantial proportion of
the discovery findings.
Conclusions
In summary, we have used a method to analyze gene
expression in serial blood samples and identified a set of
genes that show differential expression in the blood of
patients who develop ISR after BMS implantation, com-
pared to those who do not. These gene expression pat-
terns of adverse vascular remodeling suggest possible
hypotheses for the mechanisms of injury-induced remo-
deling observed in both ISR and CAD, since ISR is a
niche phenotype occurring in a subset of patients with
CAD. Further studies are needed to investigate the func-
tional relevance of these genes and are warranted based
upon the findings of this study.
Methods
Study samples
The CardioGene Study was an IRB-approved, prospec-
tive cohort study of 358 patients enrolled at the time of
bare metal stent (BMS) implantation to treat de novo,
previously untreated native coronary artery lesions at
William Beaumont Hospital (Royal Oak, Michigan,
USA) and the Mayo Clinic (Rochester, Minnesota,
USA). Patients were followed for one year to determine
ISR outcomes (Figure 1). Enrollment began in February
2002 and was closed in September 2003, prior to the
approval and clinical use of drug-eluting stents (DES) in
the United States. The protocol was approved by the
NHLBI IRB as well as the IRB at each of the clinical
enrollment sites. Informed consent was provided by
each patient. Standardized case report forms were used
to collect baseline clinical data and outcome information
in follow-up [2]. Since gene expression discovery studies
may suffer from false positives, despite the use of statis-
tical corrections for multiple hypothesis testing, we
sought out independent validation of the primary find-
ings of the CardioGene Study in a separate cohort. For
independent replication testing, 97 patients undergoing
stent implantation with BMS were enrolled in Iceland
by collaborators at Landispitali University Hospital and
University of Iceland, and RNA samples were provided
through a contract with deCODE Genetics, Inc. The
study was approved by the National Bioethics Commit-
tee and the Data Protection Authority of Iceland, and
each patient provided informed consent for participation
in the study. Clinical characteristics of both study
cohorts are summarized in Table 1.
Clinical phenotype
Consecutive patients presenting to the cardiac catheteri-
zation laboratories of the clinical enrollment sites were
approached for participation in the study. Follow-up
clinical evaluation was performed via patient interview
and review of all available medical records at 6 months
and 12 months post-stent (Figure 1). ISR was defined as
clinical restenosis [2], which was defined by ischemic
symptoms after stent implantation and evidence of flow
limitation in the treated vessel by either invasive or
non-invasive testing. Follow-up angiography was not
specifically performed for the CardioGene Study. Any
available angiographic data performed as part of each
patient’s clinical care was recorded. The Icelandic subset
had follow-up angiography of all patients at 6 months.
Quantitative coronary angiography (QCA) in the Cardi-
oGene Study was performed by a single QCA reader,
and by a TIMI core QCA center for the Icelandic
subset.
PBMC Microarray Analysis
Whole blood was sampled immediately prior to stenting,
2-4 weeks after stenting and six months post-stent. Blood
samples were collected into EDTA-containing tubes at
three times from patients enrolled in the CardioGene
Study (Figure 1), and two time from patients enrolled in
Iceland. Samples from each time point were handled
according to the standardized blood handling and RNA
isolation protocols [2], for consistency across time points
and clinical enrollment sites. PBMCs were harvested by
technicians at each clinical enrollment site following
standardized protocols for Ficoll separation of whole
blood and osmostic lysis of red blood cells, to avoid
technical variation and to minimize globin mRNA
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contamination. All blood processing was completed
within 4 hours of blood draw, at room temperature.
Snap-frozen PBMCs samples were shipped to the NIH
laboratory, and RNA isolation was performed using the
Qiagen RNA isolation protocol, with DNase treatment.
RNA labeling and microarray image analysis was accord-
ing to the Affymetrix U133A protocol. To minimize the
impact of batch-to-batch variation, the multiple samples
from each patient were processed together through all
stages, and the order of RNA labeling and microarray
hybridization was randomized. The same methods were
used in the CardioGene and deCODE study samples, and
microarray analysis was conducted on all samples at the
NIH. In both studies, technicians performing the assays
were blinded to the clinical status of patients.
Statistical Analysis
Raw image data were normalized using RMA (Robust
multichip average) normalization [44]. Several steps of
quality control were performed. These included the
investigation of the residual plots using affyPLM, gender
match using a linear discriminant analysis and shrunken
centroid method [45-47]. Probes with values less than 6
in log 2 scale in more than two thirds of samples were
excluded, and age and gender were adjusted before the
analysis [48].
In the study design of the time course of blood gene
expression profiling, the follow-up times were set at
2 weeks and 6 months for the early and late follow-up.
A window was set at each of the time points, with the
early follow-up designated as any time 2-4 weeks post-
stent and the late follow-up designated as any time
between 5-7 months for patients seen at 6 months. If
patients did not return for follow-up at the 6 month time
point, an attempt was made to have the patient provide
the late follow-up blood sample at 12 months post-stent,
at the time when final clinical ascertainment for ISR was
made. As a result of the use of time windows, we were
able to increase ascertainment of follow-up blood samples,
but the actual sample collection intervals after stent
implantation were not precisely spaced. To analyze such
data, we used the time varying intercept model using a
B-spline basis of dimension 2 based on only one knot at
the median follow-up time (which was 14 days) (Addi-
tional File 3) [49]. This is because the majority of the early
follow-up is centered around 14 days. The model was fit
under the null hypothesis using combined samples of ISR
and non-ISR patients, and under the alternative hypothesis
where separate models were fitted for ISR and non-ISR
patients, respectively. The test statistic is the improvement
in the fitted model under the alternative hypothesis from
that under the null hypothesis, as measured by the relative
difference in the residual sum of squares. The bootstrap
method was used to estimate the p-value of this test
statistic [47,49]. To obtain accuracy in estimating the
p-values, 10 million bootstrap samples were generated.
Significant probe sets were selected based on an FDR-
adjusted q-value less than 0.05 [50].
The replication analysis was performed in an indepen-
dent set of samples, using deCODE samples from
patients enrolled in Iceland, to validate probe sets iden-
tified by the time course analysis of the CardioGene
samples. We performed the same analysis using the
time varying intercept model. P-values were estimated
based on 100,000 bootstrap samples, and FDR adjusted
q-value of 0.05 was, again, used to select significant
probe sets. Here the adjustment was based on the
selected set of genes since it was a replication analysis.
As a sensitivity analysis and to evaluate whether any
random set of 46 probe sets would result in significant
results as we saw in the analysis of deCODE samples,
we randomly selected 46 probe sets, and repeated the
validation analysis. This procedure was repeated 100
times, and the number of probe sets yielding an FDR
value less than 0.05 was observed.
Data analyses were performed based on the R lan-
guage utilizing libraries freely available via the Biocon-
ductor project.
Box plots were generated using the default R software
options. The upper whisker is the data point which is
1.5 times the difference between 75th percentile and
median from the upper bound of the box, and lower
whisker is 1.5 times the difference between median and
25th percentile from the lower bound of the box. Over-
all, the whisker represents the data point which is 1.5
times the interquartile range from the box.
Finally, to evaluate genes identified in a prior studies
of ISR [23,24], we analyzed the reported genes in our
data, at the baseline timepoint comparing normalized
gene expression values between ISR cases and no-ISR
controls and also against our timecourse analysis
results.
Pathway analysis
Annotation of probe sets was done using the NetAffx
(Affymetrix U133A library set) and the DAVID/EASE
software, which provides gene name and functional
annotation of probe sets [51,52]. Analysis of over-repre-
sentation, using a Fisher’s exact test of over-representa-
tion of genes from different functional categories based
on gene ontology classifications, was performed.
Additional material
Additional file 1: Supplementary Table 1. Initial 46 probesets
identified in the timecourse analysis of the CardioGene samples.
Additional file 2: Supplementary Table 2. Gene ontology annotation
of the final 32 genes identified and validated.
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Additional file 3: Supporting Materials. Statistical methods and lists of
probe IDs discovered and replicated.
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